Pharma Stocks Below 1000

The table below shows the Pharma Stocks Below 1000 based on the Highest Market Capitalization.

Content: 

• What are Pharma Stocks?
• Best Pharma Stocks In India Below 1000
• Top Pharma Stocks Below 1000
• List Of best Pharma Stocks In India Below 1000
• Top 10 Pharma Stocks in India Below 1000
• Who Should Invest In Pharma Stocks Below 1000?
• How To Invest In The Pharma Stocks Below 1000?
• Performance Metrics Of Pharma Stocks Below 1000
• Benefits Of Investing In Pharma Stocks Below 1000
• Challenges Of Investing In Pharma Stocks Below 1000
• Introduction to Pharma Stocks Below 1000
• Top Pharma Stocks below 1000 – FAQs

What are Pharma Stocks?

Pharma stocks refer to shares of companies operating in the pharmaceutical industry. These companies research, develop, manufacture, and distribute pharmaceutical products, including prescription drugs, over-the-counter medications, and biotechnology products. Pharma stocks may also encompass companies involved in medical research, clinical trials, and healthcare services. Examples include pharmaceutical giants, biotech firms, and companies specializing in generic drugs or specialty pharmaceuticals.

Best Pharma Stocks In India Below 1000

The table below shows the Best Pharma Stocks In India Below 1000 based on 1 Year Return. 

Top Pharma Stocks Below 1000

The table below shows Top Pharma Stocks Below 1000 based on the highest day Volume.

List Of best Pharma Stocks In India Below 1000

The table below shows List Of best Pharma Stocks In India Below 1000 based on the PE Ratio. 

Top 10 Pharma Stocks in India Below 1000

The table below shows Top 10 Pharma Stocks in India Below 1000 based on the 6 month return. 

Who Should Invest In Pharma Stocks Below 1000?

Investing in pharma stocks below 1000 can appeal to a wide range of investors. It may suit those seeking exposure to the healthcare sector with a moderate budget, including individuals interested in pharmaceutical innovations and medical advancements. Additionally, investors looking for defensive stocks with stable earnings and dividend yields, or those aiming to diversify their portfolios with healthcare investments may find pharma stocks below Rs.1000 attractive.

How To Invest In The Pharma Stocks Below 1000?

To invest in pharma stocks below Rs.1000, start by researching companies within the pharmaceutical sector. Identify leading pharmaceutical companies with stocks trading below Rs.1000 on the stock market. Open a brokerage account with a reputable platform, deposit funds, and place buy orders for the selected pharma stocks within your budget. Monitor your investments regularly and stay informed about industry developments and company performance.

Performance Metrics Of Pharma Stocks Below 1000

Performance metrics of Pharma Stocks Below 1000 Rs may include:

1. Revenue Growth: Reflects the rate at which the group’s companies increase their sales over time.

2. Earnings Per Share (EPS): Indicates the profitability of each share and the potential for dividend payouts.

3. Return on Equity (ROE): Measures how effectively the group’s companies are using shareholders’ equity to generate profits.

4. Price-to-Earnings (P/E) Ratio: Compares the current market price of the stock to its earnings per share, providing insight into its valuation.

5. Dividend Yield: Represents the percentage of dividends paid relative to the stock’s price, indicating the income generated for shareholders.

6. Debt-to-Equity Ratio: Measures the level of debt financing compared to equity financing, assessing the group’s financial leverage.

7. Total Shareholder Return (TSR): Reflects the total return generated for shareholders, including dividends and capital appreciation.

Benefits Of Investing In Pharma Stocks Below 1000

Advantages of investing in  Pharma Stocks Below Rs.1000 :

1. Growth Potential: Pharma stocks below Rs.1000 offer the potential for significant growth, especially if the companies have promising drug pipelines or are entering new markets.
2. Defensive Nature: The healthcare sector, including pharmaceuticals, tends to be defensive, as demand for healthcare products remains relatively stable even during economic downturns.
3. Dividend Income: Many pharmaceutical companies pay dividends, providing a source of income for investors.
4. Innovation Opportunities: Investing in pharma stocks below Rs.1000 allows investors to participate in the innovative developments and breakthroughs in the pharmaceutical industry.
5. Diversification: Adding pharma stocks to a portfolio below Rs.1000 can diversify risk and enhance overall portfolio performance, particularly if other sectors are underperforming.

Challenges Of Investing In Pharma Stocks Below 1000

Investing in Pharma Stocks Below 1000 Rs comes with certain challenges:

1. Regulatory Risks: Pharma stocks face regulatory challenges, such as drug approvals, pricing regulations, and patent expirations, which can impact company earnings and stock performance.
2. Clinical Trials: Investing in pharma stocks below Rs.1000 carries the risk of clinical trial failures, which can lead to setbacks in drug development and significant losses for investors.
3. Competition: The pharmaceutical industry is highly competitive, with companies vying for market share and facing competition from generics, biosimilars, and other innovative therapies.
4. Patent Expirations: Patent expirations on key drugs can result in revenue declines for pharmaceutical companies, leading to stock price volatility.
5. Litigation Risks: Pharma companies may face legal challenges related to patent infringement, product liability, or regulatory violations, which can result in financial penalties and reputational damage.

Introduction to Pharma Stocks Below 1000

Pharma Stocks Below 1000 – Highest Market Capitalization

Zydus Lifesciences Ltd

The Market Cap of Zydus Lifesciences Ltd is Rs. 99,415.92 crore. The stock’s monthly return is -2.64%. Its one-year return is 86.86%. The stock is 5.18% away from its 52-week high.

Zydus Lifesciences Ltd. is an Indian company that focuses on life sciences. The company is involved in various activities such as research, development, manufacturing, marketing, and selling of a range of products. This includes finished dosage human formulations like generics and specialty formulations, as well as biosimilars and vaccines, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. 

Some of its notable products are Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (a biosimilar to Kadcyla), and Exemptia. Bilypsa targets non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), while Desidustat is used for treating anemia in chronic kidney disease patients. The company is also working on ZYIL1 to address inflammation caused by the NLRP3 inflammasome and has developed ZyCoV-D, a DNA vaccine for dealing with COVID-19.

Laurus Labs Ltd

The Market Cap of Laurus Labs Ltd is Rs. 24,264.24 crore. The stock’s monthly return is -5.85%. Its one-year return is 31.57%. The stock is 7.64% away from its 52-week high.

Laurus Labs Limited is an Indian pharmaceutical and biotechnology firm that offers a comprehensive range of Active Pharmaceutical Ingredients (APIs), intermediates, Generic Finished Dosage Forms (FDF), and Contract Research services to meet the global pharmaceutical industry’s demands. The company operates under three main segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. 

The Laurus Generics segment focuses on developing, manufacturing, and selling APIs, advanced intermediates, and oral solid formulations. The Laurus Synthesis segment is involved in producing key starting materials, intermediates, and APIs for new chemical entities. The Laurus Bio segment specializes in recombinant products and animal origin-free items for safe and virus-free biomanufacturing. The company serves customers through two geographical segments: Domestic (India) and Exports (outside India), selling APIs in 56 different countries.

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is Rs. 18,892.82 crores. The stock’s monthly return is 4.26%. Its one-year return is 103.11%. The stock is 7.31% away from its 52-week high.

Piramal Pharma Limited, an Indian pharmaceutical company, provides a range of unique pharmaceutical products through both domestic and international distribution channels. With around 17 facilities worldwide and a distribution network spanning over 100 countries, the company encompasses various subsidiaries. 

These include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing entity; Piramal Critical Care (PCC), a specialized hospital generics business; and the consumer healthcare division in India, which markets over-the-counter products. PPS offers comprehensive development and manufacturing services to generic pharmaceutical companies through a globally connected network of facilities.  

Best Pharma Stocks In India Below 1000 – 1 Year Return

Wockhardt Ltd

The Market Cap of Wockhardt Ltd is Rs. 8752.29 crore. The stock’s monthly return is -9.71%. Its one-year return is 209.92%. The stock is 18.62% away from its 52-week high.

Wockhardt Limited is a company operating in the pharmaceutical and biotechnology industry. Its activities involve the production and promotion of a wide range of pharmaceutical and bio-pharmaceutical products, active pharmaceutical ingredients (APIs), and vaccines. The company manufactures various types of dosage forms, such as sterile injectables and lyophilized products. 

Wockhardt offers a diverse portfolio of products in the areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy, and diabetology. Some of the products available in India under the brand include Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART, and VAL 450.  

SMS Pharmaceuticals Ltd

The Market Cap of SMS Pharmaceuticals Ltd is Rs. 1742.14 crores. The stock’s monthly return is -4.65%. Its one-year return is 138.44%. The stock is 7.68% away from its 52-week high.

SMS Pharmaceuticals Limited is an Indian company that specializes in the manufacturing of active pharmaceutical ingredients and their intermediates. The company’s product range includes medications for various conditions such as ulcers, inflammation, migraines, diabetes, blood clotting disorders, viral infections, and mental health issues. 

Some of their key products include ranitidine, famotidine, pantoprazole sodium, itraconazole, ibuprofen, sumatriptan, vildagliptin, tenofovir, and lamivudine. The company operates manufacturing facilities in Bachupally, Hyderabad, Telangana, and Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

Strides Pharma Science Ltd

The Market Cap of Strides Pharma Science Ltd is Rs. 8241.57 crores. The stock’s monthly return is -0.86%. Its one-year return is 136.28%. The stock is 8.53% away from its 52-week high.

Strides Pharma Science Limited is an Indian pharmaceutical company specializing in the development and production of innovative niche pharmaceutical products. The company operates under two segments: Pharmaceutical and Bio-pharmaceutical. 

With a global presence in regions such as Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, Strides Pharma Science manufactures a diverse range of pharmaceutical products in various forms including liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. They have manufacturing facilities in India (Bengaluru, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida), and Kenya (Nairobi). 

Top Pharma Stocks Below 1000 – Highest Day Volume

Morepen Laboratories Ltd

The Market Cap of Morepen Laboratories Ltd is Rs. 2571.18 crores. The stock’s monthly return is -3.18%. Its one-year return is 69.05%. The stock is 22.21% away from its 52-week high.

Morepen Laboratories Limited is a pharmaceutical company that is involved in the manufacturing, production, development, and marketing of various active pharmaceutical ingredients (APIs), as well as branded and generic formulations and home health products. Some of its APIs include Apixaban, Edoxaban, Sitagliptin, and others. The company’s finished formulations include products like Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, and more. 

Additionally, it offers home health products such as air purifiers, vaporizers, nebulizers, and stethoscopes under the brand Dr. Morepen. Subsidiaries of the company include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Syncom Formulations (India) Ltd

The Market Cap of Syncom Formulations (India) Ltd is Rs. 1316.00 crore. The stock’s monthly return is -3.36%. Its one-year return is 113.93%. The stock is 42.91% away from its 52-week high.

Syncom Formulations (India) Limited is an Indian company operating in the pharmaceutical industry. The company is involved in the production and distribution of pharmaceutical drugs and formulations, as well as trading commodities and renting properties. It manufactures and markets a variety of pharmaceutical products in different forms such as tablets, capsules, liquids, injections, ophthalmic products, syrups, and ointments. The company offers products under various categories including Cratus Life Care, Cratus Evolve, and Cratus Right Nutrition. 

Some of its products include Ciprofloxacin Tablets in different strengths, Cefazolin and Cefotaxime Injections, Ceftriaxone Injection, Cefuroxime Injection, and Gentamicin Injection.

Marksans Pharma Ltd

The Market Cap of Marksans Pharma Ltd is Rs. 7595.02 crore. The stock’s monthly return is -5.91%. Its one-year return is 103.91%. The stock is 16.48% away from its 52-week high.

Marksans Pharma Limited, headquartered in India, is a pharmaceutical company that focuses on researching, manufacturing, marketing, and selling pharmaceutical formulations. 

The company produces a wide range of products in therapeutic areas like pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic treatments. With manufacturing facilities in India, the United Kingdom, and the United States, the company specializes in the production of oral solid tablets, soft gelatin capsules, and hard capsules in Goa. Additional products like non-sterile liquids, ointments, and powder formulations are manufactured for markets in the UK, West Africa, and the Middle East from its UK facility.  .

List Of best Pharma Stocks In India Below 1000 – PE Ratio

Bliss GVS Pharma Ltd

The Market Cap of Bliss GVS Pharma Ltd is Rs. 1354.70 crores. The stock’s monthly return is -4.83%. Its one-year return is 33.35%. The stock is 36.56% away from its 52-week high.

Bliss GVS Pharma Limited specializes in developing, manufacturing, and marketing pharmaceutical formulations, including capsules, creams, gels, and various other healthcare products. The company’s pharmaceutical products include ointments, effervescent tablets, eye drops, and syrups. 

Additionally, they offer healthcare items like balms, soaps, shampoos, and petroleum jelly. Some of their well-known brands include ANOMEX, CONLAX, GACET, GSUNATE, and LONART.

Granules India Ltd

The Market Cap of Granules India Ltd is Rs. 10,292.19 crore. The stock’s monthly return is -8.23%. Its one-year return is 32.35%. The stock is 20.70% away from its 52-week high.

Granules India Limited is an Indian pharmaceutical manufacturer operating within and outside India. The company is involved in the production of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs), and finished dosages (FDs). 

With over eight manufacturing facilities, most located in India and one in the United States, Granules India Limited sells its products globally in markets such as the USA, Canada, Latin America, Europe, Asia Pacific, and India. Its wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited, and Granules Lifesciences Private Limited.

Supriya Lifescience Ltd

The Market Cap of Supriya Lifescience Ltd is Rs. 3369.01 crores. The stock’s monthly return is -2.78%. Its one-year return is 72.75%. The stock is 12.12% away from its 52-week high.

Supriya Lifescience Limited is an Indian company specializing in producing active pharmaceutical ingredients (APIs). The company manufactures bulk drugs and pharmaceutical chemicals, exporting its products to approximately 86 countries in categories such as antihistamines, anesthetics, and anti-asthma therapies. 

With a product portfolio comprising around 38 niche API products, Supriya Lifescience Limited offers remedies in therapeutic segments like antihistamines, analgesics, vitamins, anesthetics, and anti-asthmatics. The company operates manufacturing facilities in Maharashtra and produces a range of products including chlorphenamine maleate, pheniramine maleate, and bronmpheniramine maleate.

Top 10 Pharma Stocks in India Below 1000 – 6 Month Return

Shilpa Medicare Ltd

The Market Cap of Shilpa Medicare Ltd is Rs. 5421.04 crore. The stock’s monthly return is -4.79%. Its one-year return is 95.41%. The stock is 11.20% away from its 52-week high.

Shilpa Medicare Limited is an Indian pharmaceutical company that focuses on research and development, manufacturing, and sales of oncology drugs and formulations. The company’s product range includes oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic products, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales, and transdermal patches. 

Shilpa Medicare Limited supplies oncology APIs and intermediates worldwide. Its oncology and non-oncology APIs are supplied to various regulated markets such as the United States, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. The company’s non-oncology APIs include Ambroxol in Europe and Tranexamic Acid and Ursodeoxycholic Acid in India. Shilpa Medicare Limited also manufactures and sells Lenvatinib Capsules under the brand name Lenshil.

Solara Active Pharma Sciences Ltd

The Market Cap of Solara Active Pharma Sciences Ltd is Rs. 1,919.32 crore. The stock’s monthly return is 16.15%. Its one-year return is 29.55%. The stock is 23.16% away from its 52-week high.

Solara Active Pharma Sciences Limited, an India-based company, offers a wide range of commercial active pharmaceutical ingredients (APIs) and contract manufacturing services across more than 70 countries. The company primarily focuses on the API segment and provides products for both commercial use and research and development. 

Some of its key products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), and a variety of other pharmaceutical substances. Solara collaborates with pharmaceutical firms in North America, Europe, and Japan.

Amrutanjan Health Care Ltd

The Market Cap of Amrutanjan Health Care Ltd is Rs. 2263.75 crores. The stock’s monthly return stands at 9.92%. Its one-year return is 24.88%. The stock is 7.54% away from its 52-week high.

Amrutanjan Health Care Limited, an India-based company, is involved in manufacturing, distributing, and selling products related to pain management, congestion management, beverages, and hygiene. The company’s business segments consist of OTC Products, Beverages, and Others. The OTC Products segment focuses on producing items for pain relief, congestion relief, and hygiene maintenance. 

The Beverages segment is responsible for creating fruit juices and oral hydration drinks. The Others segment encompasses the pain management center. Among the company’s pain management products are Pain Balm Extra Power, Strong Pain Balm, New Maha Strong Pain Balm, Roll on, and Advanced Back Pain + Roll-On, to name a few. Its congestion management offerings include Relief Cold Rub, Relief Nasal Inhaler, Relief Cough Syrup, and Relief Swas Mint.  

Jubilant Pharmova Ltd

The Market Cap of Jubilant Pharmova Ltd is Rs. 10,744.10 crores. The stock’s monthly return is 4.96%. Its one-year return is 104.27%. The stock is 3.62% away from its 52-week high.

Jubilant Pharmova Limited, an India-based pharmaceutical company, operates through three main segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Novel Drugs. 

The Pharmaceuticals segment, managed by its subsidiary Jubilant Pharma Limited, is involved in producing and supplying a range of pharmaceutical products, including active pharmaceutical ingredients, solid dosage formulations, radiopharmaceuticals, allergy therapy products, and contract manufacturing services for sterile and non-sterile products.  

Top Pharma Stocks below 1000 – FAQs

Here are some of the Best Stock Research Articles listed based on Top Sectors (Industries), Market Cap, and Fundamental Analysis Factors:

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.